Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 33Lymphoma, Follicular 19Lymphoma, Non-Hodgkin 16Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 5Recurrence 4Neoplasms 3Leukemia, Hairy Cell 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Tumor Lysis Syndrome 1Solid Tumors 1Solid Cancers 1Oncology Patients Receiving Chemotherapy 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1Disease 1Colorectal Neoplasms 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 6ibrutinib 6Imatinib Mesylate 5ofatumumab 4Rituximab 4nilotinib 3ruxolitinib 2bosutinib 2asciminib 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Dasatinib 2ziconotide 1sodium luminolate 1posaconazole 1pegfilgrastim 1oblimersen 1obinutuzumab 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1fenebrutinib 1canakinumab 1baricitinib 1abexinostat 1Voriconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × obinutuzumab × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡